Fas Kuiters

Fas Kuiters

Fas is a retired globetrotter and former financial manager with a Dow Jones Company. After retiring early from business life due to health issues, he discovered the tremendous promise of regenerative medicine, whilst doing due diligence for his stock investments. Since that time-in 2005- he has been researching and learning about regenerative medicine and naturopathy ever since.  One of the remaining goals in life is to bridge the existing gap of understanding by patients and the general public, including investors in the space, of the progress made by the scientific community in the regenerative industry, which is difficult to comprehend by mortals, due to the complexity of the "scientific language" spoken in that field and the slow pace of change in the dominant food- and pharma industries. The results of the efforts you can read on this site.  

 

 

Sunday, 21 February 2016 23:52

Good news from Naples Italy

A subscriber to the Site had an interesting find of an article published in the Journal of Surgical Research, describing the placebo controlled clinical study of PAD (Peripheral Arterial Disease) patients with chronic ulcers treated with ADRCs from Celution. By my assessment this study is one of several European Celution device based clinical studies, which culminated in Cytori receiving market authorization (added claim to Celution for intended use of: therapy against chronic wounds- reported August 2012). As described in my other article: Another backdoor Slider,  EU regulations allow the device pathway for same day surgical and AUTOLOGOUS procedures, whereby the extracted cells remain property of the patient and ONLY can be used for this SAME patient as per the "Placed on the Market" principle.  This article is presented in "key elements" style instead of my usual long stories to keep our focus on the facts-

 

Wednesday, 19 February 2014 07:47

The One that got away

If there is one thing that MDs and scientists who briefly experiment with fat cells agree upon with their colleagues who devote most of their lives studying these cells than it would be - yes- they seem to improve blood flow nicely. But why that is, has never really been all that clear. When Zuk et al plated the approx. 2% of plastic adherent SVF back in 2001/2 they apparently also did not know, which was evidenced approx. 4 years later in 2006, when UCLA  and Pittsburgh scientists battled in court with the ownership of the invention of the stromal part in SVF at stake. Pittsburgh won that battle, since they could produce a laboratory piece of paper with the handwritten note "Mesenchymal cell?" on it and Judge Consuela Marshall decided to become a free-lance scientist by suggesting that the MSCs must have travelled to the fat from the marrow and just changed properties slightly due to their new environment. Escaping "patent profanity"- patent lawyers call that. Neat story, but nowadays we know better thanks to the monumental work of Dr. Arnold Caplan from 2011- The Mesenchymal Stem Cell- an Injury Drugstore- which you can download at the bottom of this article.

On July 27 2010, Cytori surprised its investors by announcing that approval was received (together with breast augmentation and re-construction) for: The delivery of the Celution(R) System cellular output to facilitate healing of rectal and vaginal fistulas (wounds) resulting from Crohn's disease, the first stem cell-based approval in Europe for this condition.
Up to that day, a coincidental statement by Chris Calhoun, CEO on the treatment of some patients with this disorder, was subsequently corrected by the legal department "as a slip of the tongue". This article will try to shed some light on this "mystery" approval and will explain the aspects of the condition.

Wound healing is a complex- and dynamic process of restoring cellular structures and tissue layers. The human adult wound healing process can be divided into 3 distinct phases: the inflammatory phase, the proliferative phase, and the remodeling phase.

Wouldnt it therefore be nice if we could replace this highly complex biological process, that can take months to complete for large complex wounds, by having patients using the "Holy Grail" to drink magic water taken from the "fountain of eternal youth", as Indiana Jones showed us in the movie "The last Crusade"? Yes- that would be wonderful- unfortunately realization of this fiction is far away, but ADRCs could become the "holy grail" of wound healing some day, which certainly aint fiction if you read the following

Tuesday, 01 May 2012 02:52

100% Hardcore-the power of the gemisch

This article is 100% hardcore- rather technical, so really for the happy few with ambitions to understand all that jazz. On the other hand, the introduction and its message is provided in the first half, which is really very simple- i.e. fact is, that Cytori management has regarded its shareholders as "dumbo´s" for many years. Has deceived them with "simplicity", keyword- "ischemia or bloodflow", which in itself is totally off-base in respect of the potency of the cell-mix. In the mean time having private investigators unfold and PROVE the gigantic potential of the gimish, which gimish can do so much more and which results they are surely selling now to interested parties for big bucks. This strategy brought the Company on the edge of financial collaps at several occasions in the past, resulting in heavy dilution, since they were "smelling the inflection point", instead of singing the gospel of the platform technology. And I guess everybody understands that.

Tuesday, 17 April 2012 06:50

CYTX: a Low Risk Stem Cell Play

The biotech company has had successful clinical trials yet is unloved by the market. Here's why investors should start a position now.

Written by James Anderson

Typically, early-stage biotech companies are considered to have a binary outcome. If successful with the first product that enters clinical trials the company moves on to raise more money through stock sales, enter a partnership with a large pharmaceutical company, or sell the company. In each case, investors do well. However, if the first product fails in its clinical trial, there is a good chance the company will run out of money and fail. Hence, it’s binary -- all or nothing.

Stem cell therapies have been garnering significant attention as the field of regenerative medicine starts to evolve. As one would expect, there are a number of start-up biotech companies in the field.

Saturday, 14 April 2012 16:45

Sign-on SD: Stem Cells from Fat

San Diego's Cytori banks on a new process to help damaged hearts

Getting rid of that spare tire around your middle could help your heart in more ways than you might expect, according to a San Diego biotechnology company.

Cytori Therapeutics has developed a machine that pulls stem cells and other regenerative cells out of fat so they can be re-injected into the body to repair tissue damaged by heart attack or disease.

Several studies, including some in which Cytori scientists have participated, have shown that stem cells and other regenerative material from fat can help build blood supply and restore blood flow to cardiac muscle that has been damaged by a heart attack.

Friday, 13 April 2012 11:33

The Analyst´s view

On January 24, 2010 Joe Feshbach (picture- here with his wife Cindy) published an article on his Instablog at Seeking Alpha, written by his friend, former investment banker and author of the book "Lost Star of Myth and Time"- Walter Cruttenden. An absolute classic for believers in Cytori technology. Joe was one of those believers and after attending the first Cellsociety annual meeting in San Diego in February 2011 decided with his brother Matt and other investors, to put his money where his "believes" were and started to organize the construction of a cardiac clinic on the Bahama´s using Cytori tech- i.e.Celution One. Unfortunately Joe suffered a massive heart attack on August 8 2011 whilst on a biketrip and never could see his plans come to fruition.   

Friday, 13 April 2012 06:45

A Conversation with Chris Calhoun

Written by Daniel Fromson

Cytori Therapeutics probably ranks somewhere near the top of any list of the world's most innovative medical technology companies--or at least a list of its boldest. As CEO Christopher J. Calhoun explains, the company aims to do nothing less than revolutionize health care by leading the way into an era of regenerative medicine, in which damage from cancer, heart disease, and a host of other ailments can be healed with the body's own cells.

The process relies on naturally occurring regenerative cells. "What we have done," Calhoun says, "is developed products that allow a doctor to take a small amount of fat, the same volume as about half a can of Coke

Thursday, 12 April 2012 14:42

Sharon Begley´s "Wired"- Part II

Part II- "These things have gone through the ringer in choosing a name," says biomechan-ical engineer Kent Leach of UC Davis, who has used whatever-they-are to treat bone cysts in racehorses. A stem cell, by definition, is able to differentiate into any of the 200-plus kinds of cells in the human body, just as the cells of a days-old embryo can (and do). Cytori's are unlikely to ever show that range of differentiation. But they can differentiate into fat, bone, and muscle -among other tissues—depending on which signaling molecules they are exposed to. In a petri dish, the scientists provide those "this is what you will be when you grow up" molecules. In nature—that is, an embryo in a womb—biology somehow does.

Page 2 of 3

YouTube Channels

Raccoon Lodge Latest

DailyGood.org Quotes

  • Gabriel Meyer: Stretching Identity

    DailyGood.org Oct 20, 2020 | 02:00 am

    "It's simple. The deepest stuff is the simplest stuff. You don't have to be complicated to be deep. You have to be simple to be deep. That's when you really connect. There are no intermediates in the neural reality. There's[…]

    Read more...

Copyright Information

Copyright Fas Kuiters © 2019-2020 raccoon-lodge.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.